Drug targets

BenevolentAI has idenitifed a preclinical candidate for a novel ulcerative colitis target. It is in IND/CTA-enabling studies and the company plans to advance it to move the programme into the clinic in early 2023. Scientists deployed BenevolentAI’s target ID tools and machine learning models to identify and experimentally validate a novel biological target with no prior reference in published literature […]

This paid-for advertorial by BMG Labtech appeared in DDW Volume 22, Issue 4 – Fall 2021  The efficacy and safety of drug candidates depends on the affinity to their targets. Since molecular interactions are not static, the affinity of a molecule depends on the speed of binding (association rate) and dissociation (dissociation rate) with its […]

Bristol-led research has identified specific drug targets within the neural circuits that encode memories, paving the way for significant advances in the treatment of a broad spectrum of brain disorders.  Loss of memory is a core feature of many neurological and psychiatric disorders including Alzheimer’s disease and schizophrenia. Current treatment options for memory loss are […]

New data from the Navigator Phase III trial showed that AstraZeneca and Amgen’s tezepelumab reduced exacerbations and improved lung function and nasal symptoms in patients with severe, uncontrolled asthma and comorbid nasal polyps.1   Tezepelumab is a potential first-in-class treatment that acts by targeting thymic stromal lymphopoietin (TSLP), an epithelial cytokine, and has the potential to treat a […]

Brad Hamilton, Founder and Chief Science Officer at GoodCell examines the potential of induced Pluripotent Stem Cells. Across the world, patients suffering from heart failure, donor organ rejection and many other life-altering illnesses are struggling to combat the symptoms of their conditions. What if there was a way to directly repair or replace tissues that […]

In the UK, a University of Manchester-led team of scientists has discovered that the most common form of adult blindness is probably caused by a failure of at least one of five proteins to regulate the immune system. The breakthrough could one day herald the development of transformative treatments for developing age-related macular degeneration (AMD), […]

A new experimental model that more accurately replicates the impact of respiratory infections on the lungs and upper airways has been developed through an SME and academic partnership supported by the Infection Innovation Consortium (iiCON). Led by Founding Director, Professor Janet Hemingway CBE of Liverpool School of Tropical Medicine, iiCON bridges the gap in the […]

Shaping the UK into an epicentre for complex medicines is a report by the Medicines Discovery Catapult (MDC) in partnership with the CPI, which showcases the potential for the UK in developing complex medicines. The report details the potential medical and economic impact of this field, and how the UK is poised to take further […]

The process of antibody discovery and development into a clinical candidate is one full of twists, turns and offshoots, yet one that an increasing number of researchers and companies, both small and large, have successfully navigated. This eBook released by Twist Biopharma is designed to be used as a handbook for the modern antibody development […]

Over recent years, interest in identifying new targets to modify an immune response to control a host of human diseases has sky-rocketed. Based in part on the success of several new immune cell targeted treatments for cancer, combined with the CRISPR-Cas revolution and the ability to culture primary immune cells in vitro, there is now […]